Inversago Pharma’s Phase I asset MRI-1867 for Prader-Willi Syndrome (PWS) saw its Phase Transition Success Rate (PTSR) jump seven points to 70%. The PTSR update occurred on 14 June, on the heels of the Phase I’s ClinicalTrials.gov listing changing the trial’s status to completed on 10 June. PTSR is the probability, given as a percentage, of a drug progressing successfully from one development stage to the next.
Montreal, Canada-based Inversago enrolled 40 patients in the placebo-controlled, single-ascending dose Phase I study. On 10 June, the trial’s ClinicalTrials.gov listing was changed to state the Phase I completed on 16 May. PWS, a genetic disorder affecting chromosome 15, can cause short stature and behavioural and intellectual disabilities. MRI-1867 is a cannabinoid receptor type 1 antagonist.
The Phase I update resulted in a modest one-point bump to the drug’s Likelihood of Approval (LoA), which rose to 12%. LoA is identified via GlobalData’s analysis using a combination of machine learning and its proprietary algorithm and is calculated by compounding the PTSR at each stage the drug is yet to progress through. Both LoA and PTSR can be calculated for a drug by considering characteristics like therapy area, indication and molecule type.
William Newton is a Healthcare Reporter for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.
